A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

LIPO-102 is under evaluation for treatment of abdominal adiposity

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neothetics, Inc

Criteria

Inclusion Criteria:

• 18 - 50 years old inclusive

• Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or C-PNS

• BMI < 25kg/m sq

• Stable diet and exercise and body weight

Exclusion Criteria:

• Prior treatment of abdominal subcutaneous adipose tissue

• Females within 12 months postpardum

• Known hypersensitivity to the drugs or components